Introduction
Lower middle market (LMM) healthcare private equity investing has long centered on provider platform roll-ups that seem recession-resistant and scalable. But in recent years, that strategy has begun to fray. Labor shortages, cost inflation, shrinking margins, and heightened regulatory scrutiny have made these investments less compelling. As a result, many LMM private equity firms, those targeting businesses with enterprise values between $10M-200M, are confronting a key question: Where can they invest in healthcare with confidence?
The answer lies in what happens behind the bedside. In the complex ecosystems that make modern care possible, five largely overlooked categories are quietly fueling growth. These are businesses that do not deliver patient care directly but support it. They manufacture essential products, service critical infrastructure, power software touchpoints, manage administrative complexity, or deliver outpatient therapies. Individually, each is valuable. Together, they form a durable, diversified blueprint for LMM investors eager to build meaningful platforms without depending on providers. By investing in five non-provider healthcare segments, medical product manufacturing, medical waste, patient engagement platforms, administrative outsourcing, and life sciences services, LMM private equity firms can build scalable, contract-backed businesses with lower regulatory exposure, enhanced margins through tech-enabled operating models, and clear exit paths. Ironwood has touched many of these verticals directly and indirectly through investments including Elite One, Memry Corporation, Katahdin Industries and Espire Dental.
Medical Product Manufacturing and Distribution
As healthcare becomes more personalized and preventative, the demand for specialized medical products, ranging from over-the-counter supplements to precision components used in surgical devices, continues to rise. Yet many of the businesses manufacturing these essential products remain small, founder-led, and operationally underdeveloped. That makes them prime candidates for LMM private equity firms. These businesses typically generate recurring B2B revenue through long-term contracts with pharmaceutical companies, device manufacturers or with provider organizations, and are therefore less exposed to the regulatory and reimbursement volatility of traditional provider services. However, they often have meaningful customer concentration, while lacking an established salesforce to diversify the business, requiring acquirors to invest in the function to realize growth and value enhancement. According to Grand View Research, the CDMO market alone is projected to grow at a CAGR of over 6.9% through 2030, driven by outsourcing trends and a rising demand for wellness products (Investigational New Drug CDMO Market Size Report 2030, n.d.). With the right operational enhancements and strategic acquisitions, these platforms can evolve into durable, mid-sized players attractive to larger strategic or upper-middle market buyers.
Medical Waste
Behind every clinical encounter lies a complex web of logistics, regulated waste disposal, instrument sterilization, and diagnostic equipment maintenance. These are not glamorous businesses, but they are essential to the functioning of the healthcare system. Critically, they tend to be overlooked by larger funds, fragmented across local markets, and driven by recurring service contracts, characteristics that make them ideal for LMM private equity. These companies operate in a highly regulated but underserved space where reliability, compliance, and timely service are non-negotiable. Investors who are able to expand service routes, enhance operational oversight, and invest in infrastructure to meet growing demand are poised for multiple appreciation at exit. The broader market context supports this thesis: the U.S. medical waste management market is projected to grow from $1.3B to nearly $2B by 2030, fueled by the continued shift toward outpatient care and the increasing volume of single-use medical products (Waste Management Market Size, Share, Growth Report 2030, n.d.). For LMM firms, the path is clear: consolidate regional players, invest in routing and tracking technology, and build professionalized platforms that deliver essential services. In doing so, sponsors not only unlock margin expansion but also create durable businesses with strong recurring revenue.
Tech-Enabled Patient Engagement Platforms
Patients now expect their healthcare experience to resemble the convenience and transparency of retail. Platforms that deliver digital scheduling, appointment reminders, intake forms, and follow-up communication are increasingly critical to a provider’s reputation and retention strategy. These platforms also alleviate administrative burdens, increase throughput, and drive downstream revenue. For LMM private equity firms, this represents an asset-light, high-margin growth opportunity, especially in niche specialties that have historically lagged in digital adoption. According to Accenture, over 60% of patients under 40 report they would switch providers for better digital access. Meanwhile, Grand View Research suggests that the remote patient monitoring (RPM) segment alone is projected to reach $16.9B globally by 2030, growing at a CAGR of 18.6% (Accenture, 2022). From online booking to follow-up messaging, providers that distinguish themselves by focusing on customer experience and operational consistency are poised for growth. That same philosophy can be applied to broader tech-enabled patient engagement models, particularly those built around software-as-a-service revenue and modular implementation. According to Markets and Markets, the global patient engagement solutions market is expected to grow at a 13.2% CAGR through 2028, signaling long-term tailwinds (MarketsandMarkets, 2023). LMM firms can acquire early-stage platforms, layer in vertical expertise, and partner with specialty provider groups to scale user adoption and revenue predictability.
Outsourced “Back-Office” and Compliance Services
Healthcare remains notoriously administrative. From billing and coding to credentialing and prior authorizations, providers face a growing burden of non-clinical work that requires accuracy, compliance, and speed. For small and mid-sized providers, outsourcing these functions is increasingly attractive. The global revenue cycle management (RCM) outsourcing market is projected to grow from $49.52B in 2025 to $78.34B by 2030, according to Research & Markets (Ltd, n.d.). Medical billing outsourcing in the U.S. alone is expected to more than double, reaching $17B by the same year. Despite this growth, roughly 40% of small healthcare organizations still manage these functions in-house using manual systems (The Persistence of Manual Processes in Healthcare, 2023). Companies offering outsourced RCM, credentialing, or payer contracting solutions often enjoy long-term, recurring contracts and low churn. However, they are typically under-digitized and run on legacy workflows. LMM private equity firms can add value through tech enablement, client onboarding automation, and geographic consolidation.
Life Sciences Services
As the pharmaceutical and biotech industries race to bring innovative therapies to market, they are increasingly turning to outsourced partners to manage critical parts of the development lifecycle. Behind the scenes, a growing ecosystem of CDMO and regulatory service providers are doing the heavy lifting – offering deep technical expertise, accelerating timelines, and helping companies navigate an increasingly complex regulatory environment. This shift has turned life sciences services into a powerful engine and a compelling opportunity for LMM private equity firms. These businesses are typically asset-light, highly specialized, and supported by long-term tailwinds like aging populations, rising R&D investment, and the ongoing push toward more personalized medicine. They also tend to generate recurring project-based revenue and command high margins, especially when supporting niche or highly regulated areas of the development pipeline. The deal environment reflects this momentum. In 2023, M&A activity in the life sciences industry surged to $191B by December, a 34% jump from 2022, according to EY industry reports (Baral, 2024). Even as the number of completed deals fell slightly, dropping from 126 to 118, the rise in total value highlights investor appetite for scaled, high-performing platforms. For LMM firms looking to deploy capital in healthcare, service providers to life sciences companies offer a uniquely resilient and scalable foothold. With the right operational playbook, investors can back founder-led businesses, enhance capabilities through acquisitions, and build platforms that deliver consistent returns, without being exposed to regulatory volatility or uncertainties of patient care. In a sector where precision, trust, and speed matter more than ever, the opportunity for long-term value creation is clear.
Conclusion
The future of healthcare investing does not just lie in who delivers care, it lies in how care is delivered, supported, and sustained behind the scenes. As provider platforms grow more saturated and constrained by regulation, LMM private equity firms must look elsewhere to drive returns and create lasting impact. The five sectors explored here, medical product manufacturing, medical waste, patient engagement platforms, administrative outsourcing, and life sciences services, offer an attractive risk return opportunity. What unites these businesses isn’t flash or headline appeal, rather functionality, sustainability, and enormous room for improvement. These businesses are under-digitized, undercapitalized, and underserved by institutional capital. They form the hidden infrastructure upon which every provider, clinic, and health system depends. Ultimately, these are not peripheral, they are foundational. Looking ahead, LMM investors who understand the systemic pressures shaping healthcare, from workforce burnout and reimbursement risk to patient expectations and tech adoption, will be best positioned to lead. By focusing on segments with contractual revenue, low regulatory exposure, and scalable operations, firms can weather industry volatility while building businesses that matter. This is more than a tactical shift; it is a strategic reorientation toward building the backbone of a modern, efficient, and patient-centered healthcare system.
|
